On November 29, Gelonghui reported that pku healthcare corp. (000788.SZ) announced that it recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The generic name of the drug is Hydrobromide Vortioxetine Tablets, with specifications of 5mg, 10mg, and 20mg, and the registration classification is chemical drug category 4.
Vortioxetine is a new type of antidepressant launched in 2013, known for its good clinical efficacy, notable clinical characteristics, and good safety. It inhibits the reuptake of serotonin (5-HT), leading to increased serotonin activity, and also has 5-HT3 receptor antagonistic and 5-HT1A receptor agonistic effects, while having little impact on noradrenergic and dopaminergic neurons.
